June 15, 2024

Lipid-lowering Drugs Market Size to Surpass USD 46.58 Bn by 2033

The global lipid-lowering drugs market size surpassed USD 33.12 billion in 2023 and is anticipated to be worth around USD 46.58 billion by 2033, growing at a CAGR of 3.47% from 2024 to 2033.

Key Points

  • North America led the lipid-lowering drugs market with the largest market size in 2023.
  • Asia Pacific is expected to witness the fastest growth in the market during the forecast period.
  • By drug class, the statins and combinations segment dominated the market with the highest market share in 2023.
  • By indication, the hypercholesterolemia segment projected the highest growth in the market in 2023.
  • By distribution channel, the retail pharmacies segment dominated the market with the largest share in 2023.

Lipid-lowering Drugs Market Size 2024 to 2033

The global lipid-lowering drugs market encompasses a variety of medications used to manage high levels of lipids such as cholesterol and triglycerides in the blood. This market has seen significant growth due to the rising prevalence of hyperlipidemia and associated cardiovascular diseases worldwide. Lipid-lowering drugs, such as statins, fibrates, and other cholesterol-lowering medications, play a crucial role in reducing the risk of heart disease and stroke, making them an essential part of preventive healthcare.

Get a Sample: https://www.precedenceresearch.com/sample/4124

Growth Factors

Several factors contribute to the growth of the lipid-lowering drugs market. One of the primary drivers is the increasing incidence of lifestyle-related diseases such as obesity and diabetes, which are linked to elevated cholesterol levels. Additionally, an aging population and rising awareness about the importance of maintaining healthy cholesterol levels fuel the demand for these drugs. Advances in pharmaceutical research and development have also led to the introduction of more effective lipid-lowering drugs, further boosting market growth.

Regional Insights

Regionally, North America leads the market due to its well-established healthcare infrastructure, high prevalence of cardiovascular diseases, and advanced research and development activities in the pharmaceutical sector. Europe follows closely, driven by a high awareness of health and wellness and a strong emphasis on preventive healthcare. The Asia-Pacific region is expected to witness significant growth due to increasing healthcare spending, a growing middle-class population, and rising awareness of cardiovascular health.

Lipid-lowering Drugs Market Scope

Report CoverageDetails
Global Market Size in 2023USD 33.12 Billion
Global Market Size in 2024USD 34.27 Billion
Global Market Size by 2033USD 46.58 Billion
Growth Rate from 2024 to 2033CAGR of 3.47%
Largest MarketNorth America
Base Year2023
Forecast Period2024 to 2033
Segments CoveredBy Drug, By Indication, and By Distribution Channel
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Lipid-lowering Drugs Market Dynamics

Divers and Opportunities

The lipid-lowering drugs market is driven by an increasing emphasis on preventive healthcare, rising awareness of heart health, and the availability of effective treatments. Opportunities in this market include the development of new, innovative drugs with fewer side effects and improved efficacy. There is also potential for growth in emerging markets, where healthcare infrastructure is improving, and awareness about the benefits of lipid-lowering drugs is rising.


Despite the market’s growth prospects, it faces several challenges. These include the high cost of advanced drugs, potential side effects associated with long-term use of lipid-lowering medications, and competition from alternative therapies such as dietary supplements and lifestyle changes. Additionally, stringent regulatory requirements for drug approval can slow down the introduction of new treatments to the market. Companies in this market need to navigate these challenges to continue growing and meeting the needs of patients worldwide.

Read Also: Enteral Feeding Formulas Market Size to Surpass USD 12.51 Bn by 2033

Lipid-lowering Drugs Market Recent Developments

  • In April 2024, the Indian pharmaceutical industry announced to launch an innovative cholesterol-lowering injection that aims to help in decreasing the bad level of cholesterol of LDL in the blood and also decreases heart disease risks such as heart stroke and attacks.
  • In April 2024, researchers of the Department of Biological Sciences and Bioengineering at the Technology Kanpur (IITK) launched the latest information about how cholesterol-lowering drugs such as Niacin work on the molecular level.
  • In April 2024, Amarin (NASDAQ: AMRN) Corporation plc showcased two data presentations at ACC.24 which describe the impacts of VASCEPA ®/VAZKEPA ® on decreasing adverse cardiovascular events in patients with reduced lipoprotein level or baseline high and decreases the risks of cardiovascular diseases.
  • In January 2022, Acuitas Therapeutics came in collaboration with Pfizer Inc. The company is working on the development of lipid nanoparticle (LNP) delivery systems for introducing messenger RNA (mRNA)-based therapeutics.
  • In July 2023, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio® (inclisiran)’s label update for allowing the use in patients with the higher LDL-C which increases the risk of heart disease. This patient population consists of comorbidities such as diabetes and hypertension.

Lipid-lowering Drugs Market Companies

  • Sanofi
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Ltd.
  • AbbVie, Inc.
  • Viatris (Mylan N.V.)
  • AstraZeneca PLC
  • Dr. Reddy’s Laboratories Ltd.

Segments Covered in the Report

By Drug

  • Statins & Combination
  • PCSK9 Inhibitors
  • Bile Acid Sequestrants
  • Fibrates
  • Cholesterol Absorption Inhibitors
  • Others

By Indication

  • Hypercholesterolemia
  • Coronary Artery Disease
  • High Triglycerides

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/